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Circulating 5Hydroxytryptamine Concentrations in 
Preterm Newborns 
RE. Schumacher, MD, P.M. Farrell, MD, PhD, and E.B. Olson, Jr., PhD 
Summary. Alterations in circulating 5-hydroxytryptamine (5-HT) concentrations play a role in 
the pathophysiology of respiratory failure in adults We undertook a study to develop a 
micromethod and measure circulating free 5-HT concentrations in preterm newborns with and 
without respiratory distress Forty-six samples of platelet-poor plasma were obtained from 29 
preterm newborns with varying degrees of respiratory distress Samples were taken on days 
2-3 and 6-7 of life For measuring 5-HT concentrations we used a precolumn sample en- 
hancement technique followed by ion exchange HPLC with electrochemical detection The 
assay allowed detection of extremely small (50 pg) amounts of 5-HT from small (0 2 ml) 
amounts of blood The mean 5-HT Concentration on days 2-3 was 1 77 0 74 nglml (mean 
95% confidence limits) and on days 6-7 was 0 69 f 0 23 nglml This represented a 
significant fall in 5-HT concentrations (P = 0 01) All of 16 paired serial samples fell with time 
(P = 0 006) We conclude that platelet-poor plasma 5-HT concentrations in premature new- 
borns are low, that there is a significant decline in these values over the first week of life. and 
that, in contrast with adults. the presence of respiratory failure is not associated with increased 
free 5-HT concentrations The low 5-HT concentrations seen in newborns may reflect the 
ability to increase pulmonary uptake Pediatr Pulmonol 1987; 3:117-122. 
Key words: Serotonin concentration, circulation; premature infants, low 5-HT; respira- 
tory distress, not elevated 5-HT; micromethod; precolumn sample enhance- 
ment: electrochemical detection. 
INTRODUCTION rnonary shunting and respiratory distress would exhibit 
marked alterations in circulating 5-H'I' concentrations. I t '  
tile 
henitdynamic changes seen in  the newborn respirator) transmitter and a biogenic aniine with multiple vasoactive 
properties. I t  is recognized as both a vasoconstrictor and Given [hat data regarding free s-HrI. 
a vastdilator. Animal studies of endotoxic and hemor- concentrations in healthy pretcrr,l newborns are lacking, 
rhagic shock suggest an iniportant role for S - H T  in the and [hat electrochemical detection niethtds 
ry sensitivity,"' we undertook this stud) pathophysiology of these disease states, with elevated 
pulmonary artery pressure attributed in  part to elevated a micromethod and survey circulating 5-HrI' 
reterm newborns with and without blood 5 - H T  concentration. Pretreatment with 5 - H T  . 
antagonists attenuates many o f  the cardiovascular changes respiratory dist 
seen. ' ' I n  adult humans suffering from respiratory fail- 
Serotonin o r  S-hydroxytryptamine ( S - H T )  is a neuro- present, such altcrat,ons may play a role i n  soI,le 
ure, elevated concentrations o f  free 5 - H T  (measured in 
platelet-ptwr plasma) have been Moreover, 
in one such study, the presence of pulmonary hyperten- 
sion appeared to be directly related t o  5 - H T  concentra- 
tions measured in platelet-pwr plasma. 
The pulmonary vascular endothelium actively takes up 
and metaholizes 5-H?'. Alterations in pulmonary uptake 
ability are seen with damaged endothelium such as in 
shock or prolonged hyperoxic states." ' A recent study 
using isolated pertused lungs suggests that the lung's 5- 
H T  uptake ability changes with age and that peak pul- 
monary uptake ability occurs at o r  near the time of' birth.' 
Given the above information. we hypothesized that 
premature newborns with varying degrees of  extrapul- 
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MATERIALS AND METHODS 
This study was approved by the Human Subjects Com- 
mittee of the University of Wisconsin and the Institu- 
tional Review Board of Madison General Hospital. Forty- 
six samples of platclet-poor plasma were obtained from 
29 preterm newborns. Gestational ages ranged from 25 
to 36 weeks (mean 28.5 weeks). Samples were taken on 
day 2 or 3 of life ( > 24, < 72 hr) and/or on day 6 or 7 
(> 120. < 168 hr) of life. Sixteen of these represented 
paired serial samples. On days 2-3, 17 of 27 patients 
were receiving supplemental oxygen (either by hcmd or 
with positive pressure ventilation). On days 6-7, 10 of 20 
were still receiving supplemental oxygen; however, no 
infant required any increase in the level of respiratory 
support. Of the 29 newborns studied, 17 had clinical and/ 
or radiographic findings compatible with respiratory dis- 
tress syndrome, one had an isolated patent ductus arter- 
iosus, three were ventilated for apnea, and two carried 
the clinical diagnosis of chronic pulmonary insufficiency 
of prematurity. Seven of the infants were receiving en- 
teral nutrition, but none ol'theni had been fed within 2 hr 
of the time of blood sampling. In 37 cases, blood was 
taken from an umbilical artery catheter; nine samples 
were taken from a peripheral vein. Although varying 
degrees of alveolar hypoxia were present, as measured 
by indwelling arterial saturation catheters, transcutane- 
ous oxygen monitors. or simultaneously drawn bltxld 
gases, no infant had 0 2  saturation <85% or Po? < 50 
torr during blood sampling. 
Blood (0.5 ml) was drawn into a heparinized tube and 
carried on ice to  a cold (4°C) centrifuge. Each sample 
was centrifuged for 10 min at 2,OOOX gravity, and a 
resulting sample of 0.2 ml platelet-poor plasma was 
transferred to  a vial containing 2/pg of ascorbate solution 
( 1.2 g ascorbate/ 100 ml), which served as an antioxidant. 
The sample was either frozen immediately in liquid nitro- 
gen or stored at -40°C for several days and subse- 
quently transferred to liquid nitrogen. 
Concentrations of 5-HT were measured using a precol- 
umn sample enhancement technique followed by ion ex- 
change HPLC with electrochemical detection. To 
precipitate protein, 5 p1 of 83% trichloracetic acid was 
added to each of the thawed samples; the denatured 
samples were spun at 3,OOOX gravity for 5 min and the 
resulting supernatant was used in 50 pl aliquots for injec- 
tion onto  the columns (using a Rheodyne 7125 HPLC 
injection valve). A 2 cm enhancement column packed 
with 2 5 4 0  pm diameter strong cation exchange resin 
was used in the injection loop. Following injection of the 
sample. and with the injection valve still in the load 
position, the enhancement column was rinsed with 1.7 
ml wash buffer. The injection valve was then moved to 
the inject position allowing the eluting buffer to carry the 
remaining sample from the enhancement column onto the 
10 cm separation column packed with the same resin as 
in the enhancement column. The 5-HT was detected by a 
mcxiel LC4A ampmetric detector (BAS Systems, Lafay- 
ette. IN)  using a glassy carbon electrode. The potential 
across the electrode was set at 0.65 mV. The buffers used 
as the mobile phase in liquid chromotography were pre- 
pared by adding 10.5 g citric acid, 8.2 g sodium acetate. 
4.8 g sodium hydroxide, and 2.1 ml glacial acetic acid to 
1 liter of water, which was degassed and filtered through 
a 0.45 pm vacuum filter. This solution was used to 
prepare two buffers. The wash buffer used to rinse the 
enhancement column was prepared with one part of this 
solution and three parts water. The column elution buffer 
was prepared by adding 60 ml of methanol to 1 liter of 
the filtered solution (final pH 5.  I ) .  Column flow was 
0.75 ml/min. 
Verification of the identity of the 5-HT peak was ob- 
tained by inclusion of an internal 5-HT spike to selected 
newborn plasma samples. In addition, the specificity of 
the method was further confirmed by demonstrating that 
other idoleamines, catecholamines, and their principle 
metabolites fail t o  coelute with 5-HT. When known 
amounts of 5-HT were added to patients' plasma. no 
quenching phenomenon or interference could be demon- 
strated. Recovery rate of 5-HT was essentially 100%. 
Final 5-HT concentrations were determined by compar- 
ing resultant peak heights with a standard curvc dcvel- 
oped by extracting and analyzing mock plasma samples 
(6% bovine albumin solution) prepared with known 5- 
HT concentrations ranging from 0 to 100 ng 5-HT/ml. 
Prior to and after each series of analyses, multiple injec- 
tions o f  a working standard solution of known S-HT 
concentration were analyzed to correct for any variations 
in detector sensitivity. In addition, mock plasma samples 
(6% bovine albumin solution containing a known S-HT 
concentration of approximately 1 ,  2. 5.  10, 30. or 100 
ng/ml) were prepared in 2.0 ml aliquots and stored in 
liquid nitrogen. To monitor independently the 5-HT as- 
say, selected samples of these mock plasmas were ex- 
tracted and analyzed in parallel with the analyses of 
unknown serum samples. All specimens were analyzed 
in duplicate. On occasions when the measured S-HT 
concentration differed by more than 10% from the ex- 
pected value, the mock serum extractions were repeated 
using 5-HT concentrations bracketing the estimated 5- 
HT concentration of the unknown plasmas. If necessary, 
appropriate correction factors were applied to the un- 
knowns. In this assay, with a pump flow of 0.75 ml/min, 
5-HT elution volume was 4.78 ml, and the void volume 
was 0.86 ml. 
5-HT concentrations for different patient populations 
were compared using a one-way analysis of variance with 
posthoc analysis according to the method of Scheffe. " 5- 
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HT concentrations on different days were compared us- 
ing an unpaired t test. Serial sample concentrations were 
analyzed using a paired t test. Population data are rou- 
tinely expressed by the mean * 95% confidence limits. 
RESULTS 
Micromethod 
Our assay, allowed us to measure extremely small 
amounts (<50  pg injected) of 5-HT from small (0.2 ml 
plasma) amounts of blood (Fig. 1). We found that by 
using the enhancement column in the injection loop we 
could dramatically reduce the size of the solvent front or 
void volume peak commonly seen with plasma prepara- 
tions such as ours. This technique, coupled with the 
selectivity of electrochemical detection. allowed for min- 
imal sample handling and better resolution of the 5-HT 
peak without affecting 5-HT peak height. 
Standard curves, constructed using mock plasma sam- 
ples with known 5-HT concentrations (0- 100 ng/ml), 
6 T  Colum A n I 
1 2  
l 
demonstrated a linear relationship between peak height 
(pk hgt) and 5-HT concentration ([SHT]). The linear 
regression equation for a 50 pl injection volume was pk 
hgt (mm) = 9.9516 X [5-HT] (ng/ml) + 0.6929 with a 
correlation coefficient of 0.991. Overall day-to-day vari- 
ability of the 5-HT assay estimated by the difference 
between the calculated and the actual concentration of 5- 
HT in mock plasma (5-HT concentrations ranging from 
1 to 30 ng/rnl) was -0.59 k 0.71 ng/ml. When this 
difference was expressed as a fraction of the expected 5- 
HT concentrations, the overall variability was 0.054 k 
0.061. We also demonstrated that storing samples at 
-40°C for 14 days did not appreciably alter sample 5- 
HT concentrations. 
5-HT Concentrations in Patients 
The mean platelet-poor plasma 5-HT concentration on 
days 2-3 was 1.77 f 0.74 ng/ml (mean f 05% confi- 
dence limit), range 0.20-8.60 ng/ml. On days 6-7 the 
mean concentration was 0.69 It 0.23 ng/ml, range 0.10- 
- --- 
0 10 PO 30 40 50 60 7 0  60 90 100 110 
Fig. 1. Samples of mock and patient plasma containing var- sample on HPLC column A, one on column B). The initial peak 
ious amounts of 5-HT. Each specimen was run in duplicate (one represents a vold volume. 
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2.75 ng/ml. There was a statistically significant fall in 
concentration from days 2-3 to 6-7 (P = 0.01). More- 
over, in all 16 paired serial samples, the 5-HT concentra- 
tion fell with time (P = 0.006; Fig. 2). 
We attempted to correlate 5-HT concentrations with 
the degree of respiratory insufficiency present (Table 1). 
Although on days 2-3 there was a trend towards higher 
5-HT concentrations with higher inspired oxygen con- 
centrations. using one-way analysis of variance with 
postha. analysis according to the method of Schaffe, lo 
we were unable to demonstrate any significant difference 
between the groups. Of note is that the infant with the 
highest 5-HT concentration (8.6 ng/ml) was receiving 
100% oxygen for support. 
We were unable to demonstrate a difference in 5-HT 
concentrations with respect to gestational age, sex, site 
of sampling. or platelet count. However, in that our 
sample size was small, our ability to detect small differ- 
ences was limited. 
DISCUSSION 
Recently published articles have demonstrated altera- 
tions in circulating levels of various vasoactive sub- 
stances such as vasoactive intestinal peptide, angiotensin 
11, and various prostaglandins in the neonatal respiratory 
distress syndrome. I 2 - I 4  Our assay allowed us to  measure 
extremely small and previously unreported free 5-HT 
concentrations from minimal amounts of blood. We have 
demonstrated that platelet-poor plasma concentrations of 
the vasoactive amine 5-HT are exceedingly low in the 
preterm neonate and that there appears to be a small but 
significant fall in this concentration during the tirst week 
of life. In adults. plasma 5-HT concentrations have been 
reported to be significantly elevated in patients with res- 
piratory f a i h ~ r e . ~  In our laboratory, the norindl adult 
control value for platelet-free plasma 5-HT concentration 
is 8.9 f 3.8 ng/ml (mean f 95% confidence limit), 
range 3.6-16.0 ng/ml, which compares favorably with 
adult norms generated by similar detection methods. I s  
Preterm infants with respiratory distress have tree 5-HT 
concentrations five to ten times lower than the values we 
find in normal adults. 
Previous attempts to measure blood (platelet-bound 
and -free) 5-HT concentrations in newborns met with 
1 L 1 
2-3DAYS 6-7 DAYS 
Fig. 2. Platelet-poor plasma 5-HT concentrations in 16 pre- 
mature infants on days 2-3 and 6-7. All 16 infants show a fall 
in 5-HT concentration over time (P = 0.006). The infant with 
the highest value (8.6 nglml) was receiving 100% 0 2  for respi- 
ratory support. 
varying amounts of success. A study measuring whole 
blood 5-HT taken from umbilical blood vessels at deliv- 
ery suggested that the fetus is capable of producing 5-HT 
and that fetal blood concentrations were equal to or 
greater than maternal levels.'' This was in contrast to 
other studies that found very low whole-blood 5-HT 
concentrations during the first few weeks of life. '7-'9 
Explanations for these low blood 5-HT concentrations in 
the newborn centered around immaturity of enzyme sys- 
tems involved in 5-HT synthesis, pyridoxine deficiency 
(a necessary cofactor for 5-HT synthesis), decreased ca- 
pacity for 5-HT uptake by neonatal platelets, or perhaps 
delayed release reaction of 5-HT from platelets of new- 
borns. The fact that cord-blood 5-HT concentrations can 
be high and that 5-HT-containing cells have been dem- 
onstrated in lung and gut from very early in gestation 
conflicts with the hypothesis of general enzyme immatu- 
rity as a cause for low blood 5-HT concentration. Pyri- 
doxine deficiency may contribute to low 5-HT 
TABLE 1-Relationship Between 5-HT Concentrations and Respiratory Insufficiency (Required Fiop) 
Fit,, Gehtalional [S-HTl 15-HTI 
age Average Fio, days 2-3 Average Fio, days 5-6 
. ~~ (average. weeks) _ _ _ _  days 2-3 .. . (ng/ml)h ~ days5-6 - . ~ (ng/mI)h 
.. 
>0.30 28.9 0.56 1.97 f 1.63 0.50 0.10(n = I )  
0 .25<0 .30  28.5 0 .28  1.73 f 0.42 0.28 0.98 f 1.38 
G0.25 30.0 0.23 1.56 f 1.02 0.22 0.65 * 0.19 
"Range. 
hMcan 95% confidence limit. 
(0.35- I .0)" 
concentrations, yet, to achieve such concentrations in 
virtually all newborns tested, one must hypothesize that 
all newborns are pyridoxine-deficient; this does not fit 
with the data available on pyridoxine in the newborn.20 
A decreased capacity for platelet uptake of 5-HT could 
lead to low whole-blood 5-HT levels but would likely 
lead to elevated platelet-poor 5-HT levels rather than the 
low 5-HT concentrations found in the present study. 
Moreover, platelet uptake of 5-HT is reported as normal 
in newborn.21 A delayed release reaction of 5-HT from 
neonatal platelets has been demonstrated2" and could 
lower platelet-free plasma concentrations but not the 
whole blood levels noted by others. In contrast, Suarez 
et al" have found elevated products of platelet degranu- 
lation in plasma of neonates. Platelet degrdnulation would 
be expected to increase the amount of 5-HT present in 
plasma. 
Pulmonary endothelial cells compete with platelets for 
uptake of free 5-HT. A recent study showing that the 5- 
HT uptake ability of the pulmonary endothelium seems 
to peak at or near the time of birth offers an additional 
explanation for low 5-HT concentrations, that of in- 
creased competition with platelets for 5-HT uptake. '() 
This same observation of increased uptake ability, cou- 
pled with recent observations on the role of 5-HT in the 
newborn's pulmonary vascular response,'3 led us to 
speculate on the vulnerability of newborns with respira- 
tory distress to large fluctuations in circulatory 5-HT 
concentrat ions. 
In clinical studies with adults, the role of 5-HT as a 
vasoconstrictor appears to be important. In one clinical 
trial of a specific 5-HT blocker. ketanserin, the drug was 
administered to patients with respiratory failure with re- 
sultant reductions in systemic and pulmonary artery pres- 
sure.24 Excessive 5-HT concentrations in blotd are 
thought by most to result from enhanced platelet release 
in shock states. Others have proposed increased 5-HT 
release from the hypoxic intestine. An alternative or 
additional proposal is that 5-HT is released from the lung 
itself. Neuroendocrine cells of the lung have been shown 
to  contain 5-HT and studies have demonstrated a reduc- 
tion in the 5-HT content of these cells in response to 
acute hypoxia.2s Electron niicroscopy has demonstrated 
exocytosis of 5-HT-containing granules from these pul- 
monary cells towards areas of the pulmonary vascula- 
ture.26 In humans, these 5-HT-containing neuroendocrine 
cells appear to be most numerous in the fetal and perina- 
tal period." If these observations are true, then one may 
expect that increased 5-HT uptake ability of the neonatal 
lung is developmentally timed to coincide with a poten- 
tially increased 5-HT load from pulmonary neuroendo- 
crine cells, thereby protecting the systemic circulation 
from an excessive 5-HT load. Such an arrangement would 
lead to low circulating 5-HT concentrations, as was dem- 
onstrated by our data. 
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The regulation of circulating 5-HT concentration ap- 
pears to be of a complex, multifactorial nature. This 
study serves to highlight differences in circulatory 5-HT 
concentrations in newborn vs. adult respiratory failure 
and provide new, original data for further studies into the 
nature of 5-HT metabolism in the newborn. 
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